Integrated Pharmacometrics and Systems Pharmacology Model‐Based Analyses to Guide GnRH Receptor Modulator Development for Management of Endometriosis
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Endometriosis is a gynecological condition resulting from proliferation of endometrial‐like tissue outside the endometrial cavity. Estrogen suppression therapies, mediated through gonadotropin‐releasing hormone (GnRH) modulation, decrease endometriotic implants and diminish associated pain albeit at the expense of bone mineral density (BMD) loss. Our goal was to provide model‐based guidance for GnRH‐modulating clinical programs intended for endometriosis management. This included developing an estrogen suppression target expected to provide symptomatic relief with minimal BMD loss and to evaluate end points and study durations supportive of efficient development decisions. An existing multiscale model of calcium and bone was adapted to include systematic estrogen pharmacologic effects to describe estrogen concentration‐related effects on BMD. A logistic regression fit to patient‐level data from three clinical GnRH agonist (nafarelin) studies described the relationship of estrogen with endometrial‐related pain. Targeting estradiol between 20 and 40 pg/ml was predicted to provide efficacious endometrial pain response while minimizing BMD effects. CPT: Pharmacometrics & Systems Pharmacology (2012) 1, e11; doi: 10.1038/psp.2012.10 ; advance online publication 17 October 2012
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Denosumab in postmenopausal women with low bone mineral density.
McClung, M. R., Lewiecki, E. M., Cohen, S. B., Bolognese, M. A., Woodson, G. C., Moffett, A. H., Peacock, M., Miller, P. D., Lederman, S. N., Chesnut, C. H., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044459 · Cited by 1,228
Modeling the interactions between osteoblast and osteoclast activities in bone remodeling
Lemaire, V., Tobin, F. L., Greller, L. D., Cho, C. R., & Suva, L. J. (2004) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2004.03.023 · Cited by 452
Dosage aspects of danazol therapy in endometriosis: Short-term and long-term effectiveness
Biberoglu, K. O., & Behrman, S. J. (1981) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(81)90478-6 · Cited by 267
Soysal, S. (2004) · Human Reproduction · doi:10.1093/humrep/deh035 · Cited by 227
A physiologically based mathematical model of integrated calcium homeostasis and bone remodeling
Peterson, M. C., & Riggs, M. M. (2010) · Bone · doi:10.1016/j.bone.2009.08.053 · Cited by 198
Self-citationThe effects of menopause on longitudinal bone loss from the spine
Pouilles, J. M., Tremollieres, F., & Ribot, C. (1993) · Calcified Tissue International · doi:10.1007/bf00310195 · Cited by 149
Sowers, M. R., Zheng, H., McConnell, D., Nan, B., Harlow, S. D., & Randolph, J. F. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1056 · Cited by 135
Vincent, K., Kennedy, S., & Stratton, P. (2010) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.09.056 · Cited by 132
A Minimal Mathematical Model of Calcium Homeostasis
Raposo, J. F., Sobrinho, L. G., & Ferreira, H. G. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-011870 · Cited by 67
Cited by
Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model
Kuepfer, L., Niederalt, C., Wendl, T., Schlender, J., Willmann, S., Lippert, J., Block, M., Eissing, T., & Teutonico, D. (2016) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12134 · Cited by 425
Model-Based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development
Milligan, P. A., Brown, M. J., Marchant, B., Martin, S. W., van der Graaf, P. H., Benson, N., Nucci, G., Nichols, D. J., Boyd, R. A., Mandema, J. W., et al. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.54 · Cited by 238
Self-citationSystems pharmacology for drug discovery and development: paradigm shift or flash in the pan?
Vicini, P., & van der Graaf, P. H. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.40 · Cited by 108
Peterson, M., & Riggs, M. (2015) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.20 · Cited by 77
“On September 12, 2014, the FDA Endocrine and Metabolic Drugs Advisory Committee met and discussed the biologics license application (BLA) 125511, proposed trade name NATPARA (Recombinant Human Parathyroid Hormone (rDNA) or (rhPTH[1-84]), submitted for the proposed indication of replacement for endogenous parathyroid h…”
BackgroundSelf-citationBenson, N., Matsuura, T., Smirnov, S., Demin, O., Jones, H. M., Dua, P., & van der Graaf, P. H. (2013) · Interface Focus · doi:10.1098/rsfs.2012.0071 · Cited by 20
“Data-validated systems pharmacology models such as described in this study (and in other areas such as central nervous system diseases [33], oncology [34], osteoporosis [35], endometriosis [9] and safety [36]) could be of great utility in drug discovery.”
BackgroundMethod
Metadata
- Authors
- Riggs, M., Bennetts, M., van der Graaf, P., & Martin, S.
- Venue
- CPT: Pharmacometrics & Systems Pharmacology
- Publisher
- Wiley
- Published
- 2012-10
- Volume
- 1
- Issue
- 10
- Pages
- 1-9
- ISSN
- 2163-8306 (ISSN-L)
- OpenAlex
- W2074049601
- Cited by
- 43
- References
- 9
- FWCI
- 5.23
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Integrated Pharmacometrics and Systems Pharmacology Model‐Based Analyses to Guide GnRH Receptor Modulator Development for Management of Endometriosis. https://app.cochat.ai/papers/10.1038/psp.2012.10
- The paper
- Riggs, M., Bennetts, M., van der Graaf, P., & Martin, S. (2012). Integrated Pharmacometrics and Systems Pharmacology Model‐Based Analyses to Guide GnRH Receptor Modulator Development for Management of Endometriosis. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1038/psp.2012.10
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.